TW202337459A - 蛋白酪胺酸磷酸酶抑制劑及其用途 - Google Patents

蛋白酪胺酸磷酸酶抑制劑及其用途 Download PDF

Info

Publication number
TW202337459A
TW202337459A TW112103529A TW112103529A TW202337459A TW 202337459 A TW202337459 A TW 202337459A TW 112103529 A TW112103529 A TW 112103529A TW 112103529 A TW112103529 A TW 112103529A TW 202337459 A TW202337459 A TW 202337459A
Authority
TW
Taiwan
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
aryl
heteroaryl
Prior art date
Application number
TW112103529A
Other languages
English (en)
Chinese (zh)
Inventor
傑森 羅蘭
瑟吉歐 Ｇ 都榮
Original Assignee
美商耐瑞歐醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商耐瑞歐醫療公司 filed Critical 美商耐瑞歐醫療公司
Publication of TW202337459A publication Critical patent/TW202337459A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW112103529A 2022-02-02 2023-02-01 蛋白酪胺酸磷酸酶抑制劑及其用途 TW202337459A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263305786P 2022-02-02 2022-02-02
US63/305,786 2022-02-02

Publications (1)

Publication Number Publication Date
TW202337459A true TW202337459A (zh) 2023-10-01

Family

ID=87552989

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112103529A TW202337459A (zh) 2022-02-02 2023-02-01 蛋白酪胺酸磷酸酶抑制劑及其用途

Country Status (7)

Country Link
US (1) US20250136564A1 (https=)
EP (1) EP4472976A4 (https=)
JP (1) JP2025507292A (https=)
CN (1) CN119137117A (https=)
AR (1) AR128418A1 (https=)
TW (1) TW202337459A (https=)
WO (1) WO2023150535A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20240360A (es) * 2022-02-02 2024-10-01 Nerio Therapeutics Inc Inhibidores de proteína tirosina fosfatasa y usos de estos
CN120981456A (zh) 2023-05-24 2025-11-18 金橘生物科技公司 杂环化合物及其用途
WO2025030008A1 (en) * 2023-08-02 2025-02-06 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitor combinations
CN120004876B (zh) * 2023-11-16 2026-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
RU2015140066A (ru) * 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
PE20252767A1 (es) * 2019-03-14 2025-12-22 Calico Life Sciences Llc Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos
CA3191842A1 (en) * 2020-09-11 2022-03-17 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
CN117279913A (zh) * 2021-03-11 2023-12-22 金橘生物科技公司 杂环化合物及其用途

Also Published As

Publication number Publication date
EP4472976A1 (en) 2024-12-11
US20250136564A1 (en) 2025-05-01
JP2025507292A (ja) 2025-03-18
AR128418A1 (es) 2024-05-08
EP4472976A4 (en) 2026-03-25
WO2023150535A1 (en) 2023-08-10
CN119137117A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
TW202337459A (zh) 蛋白酪胺酸磷酸酶抑制劑及其用途
CN113024544B (zh) 一种含氰基并杂环化合物及其用途
US11168088B2 (en) Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof
TW202404964A (zh) 蛋白酪胺酸磷酸酶抑制劑及其用途
CN112745335B (zh) 一种三并杂环化合物及其用途
CN116848120A (zh) 用于诱导g12d突变kras蛋白分解的喹唑啉化合物
JP2025505994A (ja) プロテインチロシンホスファターゼ阻害剤およびその使用
JP2024534801A (ja) サイロシンのプロドラッグ及び誘導体ならびにその使用
TW202342437A (zh) 蛋白酪胺酸磷酸酶抑制劑及其用途
TW201843149A (zh) 法尼醇x受體促效劑及其用途
CN118221698A (zh) Kras g12d抑制剂
CN112654622B (zh) 并环化合物、其制备方法及用途
CN118974048A (zh) 膜相关的酪氨酸和苏氨酸特异性cdc2抑制激酶(pkmyt1)抑制剂及其用途
CN115697987B (zh) 雌激素受体调节剂化合物及其用途
US12103915B2 (en) TEAD inhibitors and methods of uses thereof
CA2990583A1 (en) 1,4-disubstituted imidazole derivative
CN119630670A (zh) TNFα活性调节剂及其用途
CN114929710B (zh) 用于治疗疾病的巨环
CN118871439A (zh) 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途
CN113248497A (zh) 用作fgfr4抑制剂的稠环衍生物
BR112021015588A2 (pt) Novos derivados de n-benzil-2-fenoxibenzamida como moduladores de receptores de prostaglandina e2 (pge2)
TW202510846A (zh) 蛋白質酪胺酸磷酸酶降解劑及其用途
TW202519218A (zh) 蛋白質酪胺酸磷酸酶抑制劑之組合
JP2021080183A (ja) 新規リゾホスファチジン酸誘導体
WO2024153147A1 (zh) 一种氮杂环烷烃化合物、药物组合物及其用途